Therapeutic Compliance of Nanomedicine in Alzheimer’s Disease

Abstract

NanomedicineVol. 6, No. 7 EditorialTherapeutic compliance of nanomedicine in Alzheimer’s diseaseBarnabas WilsonBarnabas WilsonDepartment of Pharmaceutics, Dayananda Sagar College of Pharmacy, Kumaraswamy Layout, Bangalore – 560078, India. Search for more papers by this authorEmail the corresponding author at nanthalaala@gmail.comPublished Online:20 Sep 2011https://doi.org/10.2217/nnm.11.114AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: Alzheimer’s diseasebrain drug targetingnanomedicineBibliography1 Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement.3,186–191 (2007).Crossref, Medline, Google Scholar2 Ferri CP, Prince M, Brayne C et al. Alzheimer’s disease international. Global prevalence of dementia: a Delphi consensus study. Lancet366,2112–2127 (2005).Crossref, Medline, Google Scholar3 Tröster SD, Miiller U, Kreuter J. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm.61,85–100 (1990).Crossref, Google Scholar4 Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res.674,171–174 (1995).Crossref, Medline, CAS, Google Scholar5 Wilson B. Brain targeting PBCA nanoparticles and the blood–brain barrier. Nanomed.4,499–502 (2009).Link, CAS, Google Scholar6 Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm.76,189–199 (2010).Crossref, Medline, CAS, Google Scholar7 Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm.70,75–84 (2008).Crossref, Medline, CAS, Google Scholar8 Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res.1200,159–168 (2008).Crossref, Medline, CAS, Google Scholar9 Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral angiopathy. Pharm. Res.25,2674–2684 (2008).Crossref, Medline, CAS, Google Scholar10 Cui Z, Lockman PR, Atwood CS et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur. J. Pharm. Biopharm.59,263–272 (2005).Crossref, Medline, CAS, Google Scholar11 Evans DA. Estimated prevalence of Alzheimer’s disease in the United States. Milbank Q68,267–289 (1990).Crossref, Medline, CAS, Google Scholar12 Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug. Discov.6,521–532 (2007).Crossref, Medline, CAS, Google Scholar13 Muthu MS, Feng SS. Pharmaceutical stability aspects of nanomedicines. Nanomed. (Lond.)4(8),857–860 (2009).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByNanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain gliomaOpenNano, Vol. 10Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects8 July 2022 | Frontiers in Aging Neuroscience, Vol. 14Acute titanium dioxide nanoparticles exposure impaired spatial cognitive performance through neurotoxic and oxidative mechanisms in Wistar rats24 November 2021 | Biomarkers, Vol. 26, No. 8Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer's diseaseJournal of Drug Delivery Science and Technology, Vol. 61Neurotherapeutic applications of nanomedicine for treating Alzheimer's diseaseJournal of Controlled Release, Vol. 325Ipriflavone and Ipriflavone loaded albumin nanoparticles reverse lipopolysaccharide induced neuroinflammation in rats21 August 2020 | PLOS ONE, Vol. 15, No. 8Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatmentBarnabas Wilson & Geetha KM30 January 2020 | Nanomedicine, Vol. 15, No. 5Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease?Pharmacological Research, Vol. 143Drug targeting strategies into the brain for treating neurological diseasesJournal of Neuroscience Methods, Vol. 311Development of albumin-based nanoparticles for the delivery of abacavirInternational Journal of Biological Macromolecules, Vol. 81Albumin nanoparticles for the delivery of gabapentin: Preparation, characterization and pharmacodynamic studiesInternational Journal of Pharmaceutics, Vol. 473, No. 1-2The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's diseaseJournal of Controlled Release, Vol. 192Nanomedicine Based Drug Targeting in Alzheimer’s Disease: High Impact of Small CarterComparative study on effects of two different types of titanium dioxide nanoparticles on human neuronal cellsFood and Chemical Toxicology, Vol. 57Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier modelAlzheimer's Research & Therapy, Vol. 5, No. 6Emerging patents for cancer-targeted nanomedicinesPharmaceutical Patent Analyst, Vol. 1, No. 2Challenges posed by the scale-up of nanomedicinesMadaswamy S Muthu & Barnabas Wilson2 March 2012 | Nanomedicine, Vol. 7, No. 3The Blood–Brain Barrier in Alzheimer's Disease Vol. 6, No. 7 Follow us on social media for the latest updates Metrics Downloaded 592 times History Published online 20 September 2011 Published in print September 2011 Information© Future Medicine LtdKeywordsAlzheimer’s diseasebrain drug targetingnanomedicineFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download